Viruses, Vol. 14, Pages 2682: Advances in Molecular Genetics Enabling Studies of Highly Pathogenic RNA Viruses
ait
Experimental work with viruses that are highly pathogenic for humans and animals requires specialized Biosafety Level 3 or 4 facilities. Such pathogens include some spectacular but also rather seldomly studied examples such as Ebola virus (requiring BSL-4), more wide-spread and commonly studied viruses such as HIV, and the most recent example, SARS-CoV-2, which causes COVID-19. A common characteristic of these virus examples is that their genomes consist of single-stranded RNA, which requires the conversion of their genomes into a DNA copy for easy manipulation; this can be performed to study the viral life cycle i...
Source: Viruses - November 30, 2022 Category: Virology Authors: Christian Mittelholzer Thomas Klimkait Tags: Review Source Type: research
Daily briefing: How mRNA vaccines could fight Ebola
Nature, Published online: 08 November 2022; doi:10.1038/d41586-022-03661-0What an mRNA vaccine against Ebola might look like, extreme heat is costing us trillions of dollars and new ways to measure economic growth. (Source: Nature AOP)
Source: Nature AOP - November 8, 2022 Category: Research Authors: Flora Graham Source Type: research
Can mRNA vaccines transform the fight against Ebola?
Nature, Published online: 07 November 2022; doi:10.1038/d41586-022-03590-yOn the heels of successful COVID-19 mRNA vaccines, the technology could hold promise in protecting against another deadly pathogen. (Source: Nature AOP)
Source: Nature AOP - November 7, 2022 Category: Research Authors: Max Kozlov Source Type: research
Beyond COVID-19: the impact of recent pandemics on medical students and their education: a scoping review
CONCLUSION: This review provided insights into how medical students were affected by recent pandemics and their perceptions of pivoting to online education, mental health, and knowledge of the diseases. Additionally, this review showcases the various educational adaptations that emerged uniquely during the COVID-19 pandemic, such as telehealth services or video conferencing tools, that can be utilized in a post-pandemic environment.PMID:36331873 | DOI:10.1080/10872981.2022.2139657 (Source: Medical Education Online)
Source: Medical Education Online - November 4, 2022 Category: Universities & Medical Training Authors: Moneb S Bughrara Stephanie M Swanberg Victoria C Lucia Keaton Schmitz Dawn Jung Tracy Wunderlich-Barillas Source Type: research
Virus-CKB 2.0: Viral-Associated Disease-Specific Chemogenomics Knowledgebase
ACS Omega. 2022 Oct 10;7(42):37476-37484. doi: 10.1021/acsomega.2c04258. eCollection 2022 Oct 25.ABSTRACTTransmissible and infectious viruses can cause large-scale epidemics around the world. This is because the virus can constantly mutate and produce different variants and subvariants to counter existing treatments. Therefore, a variety of treatments are urgently needed to keep up with the mutation of the viruses. To facilitate the research of such treatment, we updated our Virus-CKB 1.0 to Virus-CKB 2.0, which contains 10 kinds of viruses, including enterovirus, dengue virus, hepatitis C virus, Zika virus, herpes simplex...
Source: Herpes - October 31, 2022 Category: Infectious Diseases Authors: Yixuan Hao Maozi Chen Yasmin Othman Xiang-Qun Xie Zhiwei Feng Source Type: research
Virus-CKB 2.0: Viral-Associated Disease-Specific Chemogenomics Knowledgebase
ACS Omega. 2022 Oct 10;7(42):37476-37484. doi: 10.1021/acsomega.2c04258. eCollection 2022 Oct 25.ABSTRACTTransmissible and infectious viruses can cause large-scale epidemics around the world. This is because the virus can constantly mutate and produce different variants and subvariants to counter existing treatments. Therefore, a variety of treatments are urgently needed to keep up with the mutation of the viruses. To facilitate the research of such treatment, we updated our Virus-CKB 1.0 to Virus-CKB 2.0, which contains 10 kinds of viruses, including enterovirus, dengue virus, hepatitis C virus, Zika virus, herpes simplex...
Source: Herpes - October 31, 2022 Category: Infectious Diseases Authors: Yixuan Hao Maozi Chen Yasmin Othman Xiang-Qun Xie Zhiwei Feng Source Type: research
IJERPH, Vol. 19, Pages 14105: & ldquo;You Shall Not Pass & rdquo; without a Jab: An Institutional Theory Perspective to COVID-19 Vaccine Passport Policies
IJERPH, Vol. 19, Pages 14105: “You Shall Not Pass” without a Jab: An Institutional Theory Perspective to COVID-19 Vaccine Passport Policies
International Journal of Environmental Research and Public Health doi: 10.3390/ijerph192114105
Authors:
Emmanuel Ogiemwonyi Arakpogun
Padmali Rodrigo
Femi Olan
The recent health crises (e.g., COVID-19, Ebola and Monkeypox) have pointed out huge disparities in vaccine accessibility across the world. Nonetheless, certain governments have instituted vaccine passport policies (VPPs) to manage public health, raising mixed concerns from the public. Focusing on...
Source: International Journal of Environmental Research and Public Health - October 28, 2022 Category: Environmental Health Authors: Emmanuel Ogiemwonyi Arakpogun Padmali Rodrigo Femi Olan Tags: Review Source Type: research
Forgotten Ebola vaccine could help in outbreak | Science
Merck unearths a frozen batch of an experimental vaccine it made years ago (Source: Science: Current Issue)
Source: Science: Current Issue - October 27, 2022 Category: Science Source Type: research
Genes, Vol. 13, Pages 1941: Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics
y Maepa
Adenoviral vaccines have been at the front line in the fight against pandemics caused by viral infections such as Ebola and the coronavirus disease 2019. This has revived an interest in developing these vectors as vaccines and therapies against other viruses of health importance such as hepatitis B virus (HBV). Current hepatitis B therapies are not curative; hence, chronic hepatitis B remains the major risk factor for development of liver disease and death in HBV-infected individuals. The ability to induce a robust immune response and high liver transduction efficiency makes adenoviral vectors attractive tools ...
Source: Genes - October 25, 2022 Category: Genetics & Stem Cells Authors: Tasneem Farhad Keila Neves Patrick Arbuthnot Mohube Betty Maepa Tags: Review Source Type: research
Uganda introduces its first Ebola lockdown while it waits for vaccines
Officials in Uganda have introduced a 21-day lockdown in the Mubende and Kassanda districts in a bid to tackle the ongoing outbreak (Source: New Scientist - Health)
Source: New Scientist - Health - October 19, 2022 Category: Consumer Health News Source Type: research
IJERPH, Vol. 19, Pages 13424: A Qualitative Evaluation of COVID-19 Preventative Response Activities in South Kivu, Democratic Republic of the Congo
Conclusions: Community-informed approaches are needed for effective COVID-19 preventative response programs in South Kivu, DRC. Our study identified successes and challenges in COVID-19 response activities. Future research should assess the effectiveness of integrating preventive programs with COVID-19 vaccination efforts. (Source: International Journal of Environmental Research and Public Health)
Source: International Journal of Environmental Research and Public Health - October 17, 2022 Category: Environmental Health Authors: Matthew A. Aubourg Lucien Bisimwa Jean Claude Bisimwa Presence Sanvura Camille Williams Raissa Boroto Claude Lunyelunye Jessy Timsifu Brigitte Munyerenkana Kelly Endres Peter J. Winch Justin Bengehya Ghislain Maheshe Cirhuza Cikomola Alain Mwishingo Chris Tags: Article Source Type: research
Immunogenicity of rVSV ΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials
CONCLUSION: These data demonstrate that rVSVΔG-ZEBOV-GP elicits a robust and durable immune response through 12 months postvaccination in participants regardless of age, sex, or BL GP-ELISA titer. The higher immune responses observed in women and participants with pre-existing immunity are consistent with those described previously and for other vaccines. Trials were registered as follows: PREVAIL: ClinicalTrials.gov NCT02344407; FLW: Pan African Clinical Trials Registry PACTR201503001057193; STRIVE: ClinicalTrials.gov NCT02378753. Protocols V920-009, 011, and 018.PMID:36208978 | DOI:10.1016/j.vaccine.2022.09.037 (Source: Vaccine)
Source: Vaccine - October 8, 2022 Category: Allergy & Immunology Authors: Jakub K Simon Stephen B Kennedy Barbara E Mahon Sheri A Dubey Rebecca J Grant-Klein Ken Liu Jonathan Hartzel Beth-Ann G Coller Carolee Welebob Mary E Hanson Rebecca F Grais Source Type: research
Ebola outbreak in Uganda: how worried are researchers?
Nature, Published online: 07 October 2022; doi:10.1038/d41586-022-03192-8The outbreak has already spread to five districts, and there are no proven vaccines for this species of the virus. (Source: Nature AOP)
Source: Nature AOP - October 7, 2022 Category: Research Authors: Max Kozlov Source Type: research
Recombinant vaccines in 2022: a perspective from the cell factory
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 ... (Source: Microbial Cell Factories)
Source: Microbial Cell Factories - October 5, 2022 Category: Microbiology Authors: Marianna Teixeira de Pinho Favaro, Jan Atienza-Garriga, Carlos Mart ínez-Torró, Eloi Parladé, Esther Vázquez, José Luis Corchero, Neus Ferrer-Miralles and Antonio Villaverde Tags: Review Source Type: research
‘Cycles of panic and neglect’: Head of Pandemic Prevention Institute explains its early death
When public health specialist Rick Bright launched the Pandemic Prevention Institute (PPI) under the aegis of the Rockefeller Foundation last year, he recognized that several other efforts—some old, some new—had similarly ambitious visions for how to make the world safer from pathogens. “No one can do it all,” Bright
told
Science
in October 2021, when the institute was 7 months old. “We have to now come together to decide how we divide and conquer this ecosystem.”
But as Bloomberg revealed on 26 September, Rockefeller now has unexpectedly decided to break apart PPI, to which it had pled...
Source: Science of Aging Knowledge Environment - October 3, 2022 Category: Geriatrics Source Type: research
